Geninus announces interim results of preclinical ‘anti-cancer vaccine’ at the European Association for Cancer Research

Geninus (CEO Park Woong-yang) announced on the 9th that it will present the interim results of the pre-clinical test of the anti-cancer vaccine currently under development at the European Association for Cancer Research this year (EACR 2023).

Founded in 1968, EACR is an academic society with more than 12,000 researchers from industry, academia and medicine from 100 countries worldwide as members. An academic conference is held every year to develop cancer prevention and treatment methods by discussing basic, pre-clinical and translational research on cancer in a wide range. The conference will be held in Italy for 4 days from the 12th to the 15th.

The research topic that the company will present this time is efficient tumor suppression of neoantigenic peptides identified by using the VACINUS neoantigen prediction platform based on complex ternary TCR-pMHC tumor-reactive TILs)’.

A company official said, “This experiment demonstrated the anticancer effect of the neoantigen candidates selected by Geninus’ own neoantigen derivation algorithm ‘VacPipe’ in the mouse colorectal cancer model (MC38) and melanoma model (B16F10)) “The experiment was conducted by preparing neoantigen candidates selected as peptides, injecting them as a combination therapy with a PD-1 immune checkpoint inhibitor, and confirming the results,” he explained.

According to the company, the three candidates selected by Geniners have been shown to synergize with the immune checkpoint inhibitor PD-1 in terms of anticancer efficacy. In addition, the mouse model of the administration group showed a significant increase in the survival rate compared to the control group, and showed a tumor growth inhibition effect of more than 50%.

Gyu-Young Song, Director of the Geninus New Drug Development Research Institute, said, “After announcing the immune response of an anti-cancer vaccine in an animal experiment last year, I am delighted to be able to confirm the actual anti-cancer efficacy of the anti-cancer vaccine platform this time.” We look forward to positive results that can measure effectiveness,” he said.

In the meantime, this research summary can be found on the EACR website from the 9th. The company is in the position that the final results of the pre-clinical trial will be drawn within this year.


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.